Review of rifaximin as treatment for SIBO and IBS

Bibliography

• Cremonini F, Talley NJ. Irritable bowel syndrome: epidemiology, natural history, health care seeking and emerging risk factors. Gastroenterol Clin North Am 2005;34:189-204
   PubMed Web of Science ®Google Scholar
• Malagelada JR. A symptom-based approach to making a positive diagnosis of irritable bowel syndrome with constipation. Int J Clin Pract 2006;60:57-63
   PubMed Web of Science ®Google Scholar
• Hungin APS, Chang L, Locke GR, et al. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Aliment Pharmacol Ther 2005;21:1365-75
   PubMed Web of Science ®Google Scholar
• Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002;122:1500-11
   PubMed Web of Science ®Google Scholar
• Barbara G, De Giorgio R, Stanghellini V, et al. New pathophysiological mechanisms in irritable bowel syndrome. Aliment Pharmacol Ther 2004;20(Suppl 2):1-9
   PubMed Web of Science ®Google Scholar
• Schoenfeld P. Efficacy of current drug therapies in irritable bowel syndrome: what works and does not work. Gastroenterol Clin North Am 2005;34:319-35
   PubMed Web of Science ®Google Scholar
• Lotronex [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2006
   Google Scholar
• FDA public health advisory: tegaserod maleate (marketed as Zelnorm). Food and Drug Administration. Available from: http://www.fda.gov/cder/drug/advisory/tegaserod.htm [Last accessed 10 November 2008]
   Google Scholar
• Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA 2004;292:852-8
   PubMed Web of Science ®Google Scholar
• Galatola G, Grosso M, Barlotta A, et al. Diagnosis of bacterial contamination of the small intestine using the 1g [14C] xylose breath test in various gastrointestinal diseases. Minerva Gastroenterol Dietol 1999;37:169-75
   Google Scholar
• Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000;95:3503-6
   PubMed Web of Science ®Google Scholar
• Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003;98:412-9
   PubMed Web of Science ®Google Scholar
• Nucera G, Lupascu A, Gabrielli M, et al. Sugar intolerance in irritable bowel syndrome: the role of small bowel bacterial overgrowth [DDW abstract T1783]. Gastroenterology 2004;126(4 suppl 2):A-511
   Google Scholar
• Lupascu A, Gabrielli M, Lauritano EC, et al. Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther 2005;22:1157-60
   PubMed Web of Science ®Google Scholar
• McCallum R, Schultz C, Sostarich S. Evaluating the role of small intestinal bacterial overgrowth (SIBO) in diarrhea predominant irritable bowel syndrome (IBS-D) patients utilizing the glucose breath test (GBT) [DDW abstract T1118]. Gastroenterology 2005;128(4 suppl 2):A-460
   Google Scholar
• Nucera G, Gabrielli M, Lupascu A, et al. Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2005;21:1391-5
   PubMed Web of Science ®Google Scholar
• Walters B, Vanner SJ. Detection of bacterial overgrowth in IBS using the lactulose H2 breath test: comparison with 14C-D-xylose and healthy controls. Am J Gastroenterol 2005;100:1566-70
   PubMed Web of Science ®Google Scholar
• Cuoco L, Salvagnini M. Small intestine bacterial overgrowth in irritable bowel syndrome: a retrospective study with rifaximin. Minerva Gastroenterol Dietol 2006;52:89-95
   PubMedGoogle Scholar
• Esposito I, de Leone A, Di Gregorio G, et al. Breath test for differential diagnosis between small intestinal bacterial overgrowth and irritable bowel disease: an observation on non-absorbable antibiotics. World J Gastroenterol 2007;13:6016-21
   PubMed Web of Science ®Google Scholar
• Madrid AM, Defilippi CC, Defillipi GC, et al. Small intestinal bacterial overgrowth in patients with functional gastrointestinal diseases. Rev Med Chil 2007;135:1245-52
   PubMed Web of Science ®Google Scholar
• Majewski M, McCallum RW. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial. Adv Med Sci 2007;52:139-42
   PubMed Web of Science ®Google Scholar
• Carrara M, Desideri S, Azzurro M, et al. Small intestine bacterial overgrowth in patients with irritable bowel syndrome. Eur Rev Med Pharmacol Sci 2008;12:197-202
   PubMed Web of Science ®Google Scholar
• Bratten JR, Spanier J, Jones MP. Lactulose breath testing does not discriminate patients with irritable bowel syndrome from healthy controls. Am J Gastroenterol 2008;103:958-63
   PubMed Web of Science ®Google Scholar
• Grover M, Kanazawa M, Palsson OS, et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: association with colon motility, bowel symptoms, and psychological distress. Neurogastroenterol Motil 2008;20(9):998-1008
   PubMed Web of Science ®Google Scholar
• Scarpignato C, Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion 2006;73(suppl 1):13-27
   PubMed Web of Science ®Google Scholar
• Baker DE. Rifaximin: a nonabsorbed oral antibiotic. Rev Gastroenterol Disord 2005;5:19-30
   PubMedGoogle Scholar
• Xifaxan [package insert]. Morrisville, NC: Salix Pharmaceuticals, Inc; 2008
   Google Scholar
• DuPont HL. New antibacterial agents in the management of acute infectious diarrhea. Clin Update Infect Dis 2004;7:1-4. Available from: http://www.nfid.org/pdf/id_archive/acutediarrhea.pdf [Last accessed 10 November 2008]
   Google Scholar
• Taylor DN, McKenzie R, Durbin A, et al. Systemic pharmacokinetics of rifaximin in volunteers with shigellosis. Antimicrob Agents Chemother 2008;52:1179-81
   PubMed Web of Science ®Google Scholar
• Descombe JJ, Dubourg D, Picard M, Palazzini E. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res 1994;14:51-6
   PubMedGoogle Scholar
• Pentikis HS, Connolly M, Trapnell CB, et al. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers. Pharmacother 2007;27:1361-9
   PubMed Web of Science ®Google Scholar
• Trapnell CB, Connolly M, Pentikis H, et al. Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/norgestimate in healthy females. Ann Pharmacother 2007;41:222-8
   PubMed Web of Science ®Google Scholar
• Jiang ZD, Ke S, Palazzini E, et al. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother 2000;44:2205-6
   PubMed Web of Science ®Google Scholar
• Lauritano EC, Gabrielli M, Lupascu A, et al. Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2005;22:31-5
   PubMed Web of Science ®Google Scholar
• Lauritano EC, Lupascu A, Scarpellini E, et al. A dose-finding study of rifaximin in the treatment of small bowel bacterial overgrowth in patients with irritable bowel syndrome [DDW abstract M1174]. Gastroenterology 2006;130(4 suppl 2):A-317
   Google Scholar
• Scarpellini E, Gabrielli M, Lauritano CE, et al. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2007;25:781-6
   PubMed Web of Science ®Google Scholar
• Pimentel M, Park S, Mirocha J, et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of irritable bowel syndrome: a randomized trial. Ann Intern Med 2006;145:557-63
   PubMed Web of Science ®Google Scholar
• Sharara AI, Aoun E, Abdul-Baki H, et al. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 2006;101:326-33
   PubMed Web of Science ®Google Scholar
• Yang J, Lee HR, Low K, et al. Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci 2008;53:169-74
   PubMed Web of Science ®Google Scholar
• Lembo A, Zakko S, Ferreira N, et al. Rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: short term treatment leading to long term sustained response [DDW abstract T1390]. Gastroenterology 2008;134:A-545
   Google Scholar
• Ringel Y, Zakko S, Ferreira N, et al. Predictors of clinical response from a phase 2 multi-center efficacy trial using rifaximin, a gut-selective, nonabsorbed antibiotic for the treatment of diarrhea-associated irritable bowel syndrome [DDW abstract T1411]. Gastroenterology 2008;134:A-550
   Google Scholar
• Baidoo L, Kundu R, Berenbaum PL, et al. Rifaximin is effective therapy for small bowel bacterial overgrowth [DDW abstract W1732]. Gastroenterology 2005;128(4 suppl 2):A-672
   Google Scholar
• Majewski M, Sostarich S, Foran P, McCallum RW. Is rifaximin effective treatment for small intestinal bacterial overgrowth? [ACG abstract 293]. Am J Gastroenterol 2006;101(suppl):S141
   Google Scholar
• Lupascu A, Lauritano C, Gabrielli M, et al. Antibiotic treatment in small bowel bacterial overgrowth in patients with irritable bowel [DDW abstract 1741]. Gastroenterology 2005;128(suppl 2):A-674
   Google Scholar
• Gabrielli M, Lauritano C, Scarpellini E, et al. Rifaximin versus systemic antibiotics for the treatment of small bowel bacterial overgrowth [DDW abstract S1165]. Gastroenterology 2007;132(4 suppl 2):A-187
   Google Scholar
• Rifaximin 3 times/day for non-constipation IBS (TARGET 2). Available from: http://clinicaltrials.gov/ct2/show/NCT00724126?term=rifaximin&rank=6 [Last accessed 10 November 2008]
   Google Scholar
• Koo HL, DuPont HL. Current and future developments in travelers' diarrhea therapy. Expert Rev Anti Infect Ther 2006;4:417-27
   PubMedGoogle Scholar